Loomba, Rohit

Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors

Huang, D. Q., Mathurin, P., Cortez-Pinto, H., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology

Alcohol Consumption and Health EffectsSubstance Abuse Treatment and Outcomes

Cited by 553

Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials: Hepatology

Noureddin, M., Lam, J., Peterson, M. R., Middleton, M., Hamilton, G., Le, T.-A., Bettencourt, R., Changchien, C., Brenner, D. A., Sirlin, C., et al. (2013) · Hepatology

Liver Disease Diagnosis and TreatmentAdvanced MRI Techniques and Applications

Cited by 550

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

Sanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio, D., Kundu, S., Noviello, S., et al. (2018) · The Lancet

Liver Disease Diagnosis and TreatmentFibroblast Growth Factor Research

Cited by 550

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

Loomba, R., Lawitz, E., Mantry, P. S., Jayakumar, S., Caldwell, S. H., Arnold, H., Diehl, A. M., Djedjos, C. S., Han, L., Myers, R. P., et al. (2018) · Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 549

Semaglutide 2· 4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

Loomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., et al. (2023) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 533

Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH

Loomba, R., Sanyal, A. J., Kowdley, K. V., Bhatt, D. L., Alkhouri, N., Frias, J. P., Bedossa, P., Harrison, S. A., Lazas, D., Barish, R., et al. (2023) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentFibroblast Growth Factor Research

Cited by 522

Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement

Fix, O. K., Hameed, B., Fontana, R. J., Kwok, R. M., McGuire, B. M., Mulligan, D. C., Pratt, D. S., Russo, M. W., Schilsky, M. L., Verna, E. C., et al. (2020) · Hepatology

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 473

NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Harrison, S. A., Rinella, M. E., Abdelmalek, M. F., Trotter, J. F., Paredes, A. H., Arnold, H. L., Kugelmas, M., Bashir, M. R., Jaros, M. J., Ling, L., et al. (2018) · The Lancet

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 425

Global Prevalence of Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-Analysis

En Li Cho, E., Ang, C. Z., Quek, J., Fu, C. E., Lim, L. K. E., Heng, Z. E. Q., Tan, D. J. H., Lim, W. H., Yong, J. N., Zeng, R., et al. (2023) · Gut

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 380

Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study

Ratziu, V., Sanyal, A., Harrison, S. A., Wong, V. W., Francque, S., Goodman, Z., Aithal, G. P., Kowdley, K. V., Seyedkazemi, S., Fischer, L., et al. (2020) · Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 378

Association of histologic disease activity with progression of nonalcoholic fatty liver disease

Kleiner, D. E., Brunt, E. M., Wilson, L. A., Behling, C., Guy, C., Contos, M., Cummings, O., Yeh, M., Gill, R., Chalasani, N., et al. (2019) · JAMA Network Open

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 372

Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension

Chalasani, N., Abdelmalek, M. F., Garcia-Tsao, G., Vuppalanchi, R., Alkhouri, N., Rinella, M., Noureddin, M., Pyko, M., Shiffman, M., Sanyal, A., et al. (2020) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 358

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

Hartman, M. L., Sanyal, A. J., Loomba, R., Wilson, J. M., Nikooienejad, A., Bray, R., Karanikas, C. A., Duffin, K. L., Robins, D. A., & Haupt, A. (2020) · Diabetes Care

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 351

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

Loomba, R., Kayali, Z., Noureddin, M., Ruane, P., Lawitz, E. J., Bennett, M., Wang, L., Harting, E., Tarrant, J. M., McColgan, B. J., et al. (2018) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 340

A Gut Microbiome Signature for Cirrhosis Due to Nonalcoholic Fatty Liver Disease

Caussy, C., Tripathi, A., Humphrey, G., Bassirian, S., Singh, S., Faulkner, C., Bettencourt, R., Rizo, E., Richards, L., Xu, Z. Z., et al. (2019) · Nature Communications

Gut microbiota and healthLiver Disease Diagnosis and Treatment

Cited by 338

Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases

Stine, J. G., Wentworth, B. J., Zimmet, A., Rinella, M. E., Loomba, R., Caldwell, S. H., & Argo, C. K. (2018) · Alimentary Pharmacology & Therapeutics

Liver Disease Diagnosis and TreatmentHepatocellular Carcinoma Treatment and Prognosis

Cited by 336

ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P

Kim, J. Y., Garcia-Carbonell, R., Yamachika, S., Zhao, P., Dhar, D., Loomba, R., Kaufman, R. J., Saltiel, A. R., & Karin, M. (2018) · Cell

Liver Disease Diagnosis and TreatmentEndoplasmic Reticulum Stress and Disease

Cited by 333

A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes

Ajmera, V., Cepin, S., Tesfai, K., Hofflich, H., Cadman, K., Lopez, S., Madamba, E., Bettencourt, R., Richards, L., Behling, C., et al. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 327

Supplementation of Saturated Long-Chain Fatty Acids Maintains Intestinal Eubiosis and Reduces Ethanol-induced Liver Injury in Mice

Chen, P., Torralba, M., Tan, J., Embree, M., Zengler, K., Stärkel, P., van Pijkeren, J.-P., DePew, J., Loomba, R., Ho, S. B., et al. (2015) · Gastroenterology

Gut microbiota and healthAlcohol Consumption and Health Effects

Cited by 322

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 321

Meta‐analysis: pioglitazone improves liver histology and fibrosis in patients with non‐alcoholic steatohepatitis

Boettcher, E., Csako, G., Pucino, F., Wesley, R., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 318

Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis

Tan, D. J. H., Ng, C. H., Lin, S. Y., Pan, X. H., Tay, P., Lim, W. H., Teng, M., Syn, N., Lim, G., Yong, J. N., et al. (2022) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and Treatment

Cited by 307

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis

LOOMBA, R., LUTCHMAN, G., KLEINER, D. E., RICKS, M., FELD, J. J., BORG, B. B., MODI, A., NAGABHYRU, P., SUMNER, A. E., LIANG, T. J., et al. (2009) · Alimentary Pharmacology & Therapeutics

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 299

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Loomba, R., Noureddin, M., Kowdley, K. V., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N., Caldwell, S. H., Goodman, Z., et al. (2021) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 296